12:00 AM
 | 
Jul 14, 2008
 |  BioCentury  |  Regulation

Defining safety issues

Defining safety issues

“Significant safety issues,” as defined by the memorandum of agreement between CDER’s Office of Surveillance and Epidemiology (OSE) and its Office of New Drugs (OND).
...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >